EUVIMEDEUVIMED entdecken
Crossref

Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal

Meghan E Peterson, Megan P Jaynes, Sarah Berardi, Colleen Morton

Journal of Thrombosis and Thrombolysis · 2024

DOI: 10.1007/s11239-024-02969-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2024. Verfasst von Meghan E Peterson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA. meghan.…. Hauptthemen laut MEDLINE: Warfarin, Blood Coagulation Factors, International Normalized Ratio. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-activated four-factor prothrombin complex concentrate (4 F-PCC) has emerged as the preferred reversal strategy for patients on warfarin with life-threatening bleeding. Current dosing recommendations for 4 F-PCC require pre-treatment international normalized ratio (INR) and bodyweight values, resulting in ordering and administration delays. Studies have shown that alternative dosing regimens are safe and efficacious. This retrospective, single-center, pre- and post-protocol analysis was conducted to assess the efficacy of a pharmacist driven modified fixed-dose 4 F-PCC regimen versus package insert weight- and INR-based dosing regimen for warfarin reversal. The primary outcome was achievement of INR less than two. Secondary outcomes included dose and cost of 4 F-PCC, a time analysis, incidence of concomitant vitamin K administration, and incidence of thrombosis within seven days of 4 F-PCC. There were 195 patients included in the analysis, with 74 in the pre-cohort and 121 in the post-cohort. Baseline characteristics were similar between cohorts with the most common indication for warfarin use being atrial fibrillation (48.6% versus 47.1%) and reversal being intracerebral hemorrhage (68.9% versus 43.0%). Achievement of the primary endpoint occurred in 92% versus 95% (p = 0.097) of patients. A statistically significant difference was seen between cohorts regarding median dose and cost of 4 F-PCC administered (p < 0.001). Eleven thromboembolic events occurred with three events in the pre-cohort and eight events in the post-cohort (p = 0.453). A fixed-dose of 1500IU of 4 F-PCC was effective in reversing INR to less than two in most patients regardless of reversal indication with minimal thrombotic risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinBlood Coagulation FactorsInternational Normalized RatioHumansRetrospective StudiesAgedMaleFemaleHemorrhageMiddle AgedAnticoagulantsAged, 80 and overAtrial FibrillationThrombosis

Stichwörter der Autor:innen

HemostasisProthrombin complex concentrateReversalVitamin K antagonistWarfarin

Substanzen

WarfarinBlood Coagulation Factorsprothrombin complex concentratesAnticoagulants

Autor:innen und Institutionen

  • Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA. meghan.peterson@vumc.org.
  • Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA.
  • Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Zitieren

APA

Peterson, M. E., Jaynes, M. P., Berardi, S., & Morton, C. (2024). Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-024-02969-0

Vancouver

Peterson ME, Jaynes MP, Berardi S, Morton C. Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal. Journal of Thrombosis and Thrombolysis. 2024. doi:10.1007/s11239-024-02969-0

BibTeX
@article{Peterson2024,
  author = {Peterson, Meghan E and Jaynes, Megan P and Berardi, Sarah and Morton, Colleen},
  title = {Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2024},
  doi = {10.1007/s11239-024-02969-0}
}
Kostenlos starten →